Doctors and physicians are increasingly considering cannabis for the opioid epidemic as its use could save countless lives.

The ongoing opioid epidemic is one of the greatest mass public health crises facing humanity today. According to the World Health Organization, an estimated 27 million people worldwide suffered from opioid addiction in 2016 and approximately 450,000 people died of a result of drug use in 2015. By underestimating the addictive power of opioids, millions of patients have been exposed to debilitating addiction issues. The lack of alternatives to opioid pain relief has resulted in immeasurable human misery and loss of life, leading many to consider using cannabis for the opioid epidemic.

With the true dangers of opioids now tragically clear, the medical and scientific communities are looking to other pain relief options. Medicinal cannabis could present the answer. One study by researchers at the University of California San Diego and Weill Cornell Medical College found that US states that had legalized medical cannabis between 1993 and 2014 saw a nearly 40 percent reduction in opioid use by Medicaid enrollees. The pain relief properties of cannabinoids like cannabidiol (CBD) and tetrahydrocannabinol (THC) have been well known for decades; however, the relaxation of cannabis laws and the subsequent surge of cannabis research have legitimized cannabis as a healthy alternative to opioids.

 

What you need to know about Tesla's Battery Day

   
Expert Analysis of Tesla's Battery Day and the impact on Battery Metals Investing.

This development is one of the greatest opportunities for growth and innovation in the medical cannabis space today.

The opioid epidemic

The National Institute on Drug Abuse traces the origin of the modern opioid epidemic to the late 1990s, when oxycontin and other pharmaceutical opioids created by major pharmaceutical companies gained popularity. At the time, pharmaceutical companies assured physicians that addiction to these drugs was uncommon, causing prescription rates to rise steadily into the 2000s. Concurrently, diverted pharmaceutical opioids have become common on the black market alongside street opioids like heroin.

The numbers associated with the opioid epidemic are staggering. In the United States alone, there were 70,237 overdose deaths in 2017, a 9.6 percent increase from the previous year, according to the Centers for Disease Control. In Canada, more than 9,000 opioid-related deaths occurred between January and June 2016, according to the federal government’s statistics. According to the National Institute on Drug Abuse, roughly 21 percent of people who are prescribed opioids end up misusing them, and between 21 and 29 percent of patients misusing opioids develop an addiction to them. Of those who misuse, 4 to 6 percent eventually turn to heroin. Approximately 80 percent of heroin users initially misused prescription opioids.

The potential of medical cannabis

One of the root causes of today’s opioid crisis is related to an over-reliance on opioids as a means of prescription pain relief. Historically, medical professionals have underestimated the addictive properties that led physicians to prescribe these drugs for all types of chronic and acute pain. Today, we have a better understanding of the risks associated with opioid medications, but the need for pain treatment remains. This is where cannabis’ potential has been most apparent. Patients have been turning to medical cannabis for pain in legal jurisdictions for decades now and a growing body of research is helping to legitimize cannabis treatment as a legitimate alternative to opioids. The hope is that if more people can be treated with cannabis rather than opioids, then fewer people will be put at risk.

Cannabis producers see the opportunity presented by this desperate need. Major cannabis companies like Aurora Cannabis (TSX:ACB,NYSE:ACB) and Tilray (NASDAQ:TLRY) have been involved in studies regarding the efficacy of cannabis-based pain relief. Medical cannabis companies like Orion Nutraceuticals (CSE:ORI) are developing cannabis products specifically for the pain relief market.

“Medical research on the benefits of cannabis is still in its infancy,” said Jonathan Fiteni, CEO of Orion Nutraceuticals. “Every day, new studies are being released that continue to show the seemingly limitless benefits derived from the plant.”

Government regulators in medical cannabis jurisdictions have clearly recognized the potential for cannabis to curb opioid addiction. The New York State Department of Health, for example, put out a guidance in July 2018 urging doctors to consider cannabis for the opioid epidemic as an alternative to prescribing opioids to patients suffering from severe pain. The states of New Jersey and Pennsylvania have put out similar statements as well.

 

What you need to know about Tesla's Battery Day

   
Expert Analysis of Tesla's Battery Day and the impact on Battery Metals Investing.

Prevention of opioid addiction is the first line of defense in the opioid crisis, but there are already millions of people around the world currently suffering from addiction. For those who are attempting to break out of the cycle of addiction, opioid withdrawal is an agonizing but unavoidable process. Withdrawal symptoms are commonly treated with opioid replacement therapies like methadone or buprenorphine, but these opioid-based treatments carry many of the same risks of dependency and withdrawal as the substances they replace while limiting the brain’s ability to naturally produce dopamine. This has led to interest in the potential of cannabinoids as alternative treatments for withdrawal symptoms and nascent evidence suggests that cannabinoids may indeed be a viable treatment to lessen symptoms during the acute opioid withdrawal period. More data is required to reach a definitive conclusion, but if this promising research holds true, cannabis could provide an extraordinary tool for combating addiction.

For decades it has been extremely difficult to conduct peer-reviewed research on the efficacy of medical cannabis in the United States. While THC-rich cannabis currently retains its Schedule 1 status at the US federal level, legal breakthroughs of the past two decades in several jurisdictions have allowed researchers to begin closing the knowledge gap. Additionally, the passing of the 2018 US farm bill has removed CBD from the Schedule 1 list, enabling easier access for researchers.

In late 2018, Columbia University was awarded a grant from the National Institute on Drug Abuse to conduct a comprehensive investigation on cannabis’ potential to reduce opioid use and overdose risk in chronic pain patients. The grant was awarded following a pilot study that found nearly two-thirds of patients were able to reduce or stop opioid use.

Takeaway

Cannabis may be the most promising option to replace opioids as a means to relieve pain. While it is still too early to state definitively that medical cannabis is the answer to the opioid crisis, the growing body of research is helping to provide legitimacy. As more medical cannabis companies continue to innovate and consider alternative options like cannabis for the opioid epidemic, the resulting growth of the industry could save countless lives.


This INNSpired article was written according to INN editorial standards to educate investors.

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less